These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 23602044)

  • 1. A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy.
    Bakhtiani PA; Zhao LM; El Youssef J; Castle JR; Ward WK
    Diabetes Obes Metab; 2013 Dec; 15(12):1065-70. PubMed ID: 23602044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon in artificial pancreas systems: Potential benefits and safety profile of future chronic use.
    Taleb N; Haidar A; Messier V; Gingras V; Legault L; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 Jan; 19(1):13-23. PubMed ID: 27629286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safe glycemic management during closed-loop treatment of type 1 diabetes: the role of glucagon, use of multiple sensors, and compensation for stress hyperglycemia.
    Ward WK; Castle JR; El Youssef J
    J Diabetes Sci Technol; 2011 Nov; 5(6):1373-80. PubMed ID: 22226254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home.
    Blauw H; van Bon AC; Koops R; DeVries JH;
    Diabetes Obes Metab; 2016 Jul; 18(7):671-7. PubMed ID: 26996542
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.
    Pozzilli P; Battelino T; Danne T; Hovorka R; Jarosz-Chobot P; Renard E
    Diabetes Metab Res Rev; 2016 Jan; 32(1):21-39. PubMed ID: 25865292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual-hormone artificial pancreas: benefits and limitations compared with single-hormone systems.
    Peters TM; Haidar A
    Diabet Med; 2018 Apr; 35(4):450-459. PubMed ID: 29337384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM.
    Kanc K; Janssen MM; Keulen ET; Jacobs MA; Popp-Snijders C; Snoek FJ; Heine RJ
    Diabetologia; 1998 Mar; 41(3):322-9. PubMed ID: 9541173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy determinants of subcutaneous microdose glucagon during closed-loop control.
    Russell SJ; El-Khatib FH; Nathan DM; Damiano ER
    J Diabetes Sci Technol; 2010 Nov; 4(6):1288-304. PubMed ID: 21129323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diabetes: Artificial pancreas--first head-to-head comparison of dual-hormone and single-hormone systems.
    Holmes D
    Nat Rev Endocrinol; 2015 Feb; 11(2):63. PubMed ID: 25511314
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.
    Weisman A; Bai JW; Cardinez M; Kramer CK; Perkins BA
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):501-512. PubMed ID: 28533136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors influencing the effectiveness of glucagon for preventing hypoglycemia.
    Castle JR; Engle JM; El Youssef J; Massoud RG; Ward WK
    J Diabetes Sci Technol; 2010 Nov; 4(6):1305-10. PubMed ID: 21129324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Glucagon in Automated Insulin Delivery.
    Wilson LM; Jacobs PG; Castle JR
    Endocrinol Metab Clin North Am; 2020 Mar; 49(1):179-202. PubMed ID: 31980117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
    McCall AL; Farhy LS
    Minerva Endocrinol; 2013 Jun; 38(2):145-63. PubMed ID: 23732369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors affecting the success of glucagon delivered during an automated closed-loop system in type 1 diabetes.
    Bakhtiani PA; El Youssef J; Duell AK; Branigan DL; Jacobs PG; Lasarev MR; Castle JR; Ward WK
    J Diabetes Complications; 2015; 29(1):93-8. PubMed ID: 25264232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.